AU2016257338B2 - Heterocyclic compounds and their use in preventing or treating bacterial infections - Google Patents
Heterocyclic compounds and their use in preventing or treating bacterial infections Download PDFInfo
- Publication number
- AU2016257338B2 AU2016257338B2 AU2016257338A AU2016257338A AU2016257338B2 AU 2016257338 B2 AU2016257338 B2 AU 2016257338B2 AU 2016257338 A AU2016257338 A AU 2016257338A AU 2016257338 A AU2016257338 A AU 2016257338A AU 2016257338 B2 AU2016257338 B2 AU 2016257338B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- alkyl
- oxo
- oct
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC(CN1C2)=CC2N(*)C1=O Chemical compound CC(CN1C2)=CC2N(*)C1=O 0.000 description 22
- GTDZRCHHWHXSRA-LPRJTOQXSA-N C/C=C/[P+](c1ccccc1)(c1ccccc1)c1ccccc1 Chemical compound C/C=C/[P+](c1ccccc1)(c1ccccc1)c1ccccc1 GTDZRCHHWHXSRA-LPRJTOQXSA-N 0.000 description 1
- YCUWZRTWPPTYSN-UHFFFAOYSA-N C=CCON(C(CN1C2)C=C2I)C1=O Chemical compound C=CCON(C(CN1C2)C=C2I)C1=O YCUWZRTWPPTYSN-UHFFFAOYSA-N 0.000 description 1
- YDSKVLKPSPLMJR-UHFFFAOYSA-N C=CCON(C(CN1C2)C=C2[n]2nccc2)C1=O Chemical compound C=CCON(C(CN1C2)C=C2[n]2nccc2)C1=O YDSKVLKPSPLMJR-UHFFFAOYSA-N 0.000 description 1
- QZWIXLPWMGHDDD-UHFFFAOYSA-N CC(C=C1)=NNC1=O Chemical compound CC(C=C1)=NNC1=O QZWIXLPWMGHDDD-UHFFFAOYSA-N 0.000 description 1
- BOXDNKOICZGEDY-UHFFFAOYSA-N CC1(C)OB(C(C(C2)N3OCC=C)=CCN2C3=O)OC1(C)C Chemical compound CC1(C)OB(C(C(C2)N3OCC=C)=CCN2C3=O)OC1(C)C BOXDNKOICZGEDY-UHFFFAOYSA-N 0.000 description 1
- ASDBEQDGWNZIHR-UHFFFAOYSA-N CCOC(C(ON(C1C(c2c[o]nc2)=CCN2C1)C2=O)(F)F)=O Chemical compound CCOC(C(ON(C1C(c2c[o]nc2)=CCN2C1)C2=O)(F)F)=O ASDBEQDGWNZIHR-UHFFFAOYSA-N 0.000 description 1
- ZPJPLSIVPJSHHM-UHFFFAOYSA-N CN(C(C=C1)=O)N=C1C(C(C1)N2OCC=C)=CCN1C2=O Chemical compound CN(C(C=C1)=O)N=C1C(C(C1)N2OCC=C)=CCN1C2=O ZPJPLSIVPJSHHM-UHFFFAOYSA-N 0.000 description 1
- APMYDWRKEPGINQ-UHFFFAOYSA-N CN(C=C(C=N1)C(C(C2)N3OCC=C)=CCN2C3=O)C1=O Chemical compound CN(C=C(C=N1)C(C(C2)N3OCC=C)=CCN2C3=O)C1=O APMYDWRKEPGINQ-UHFFFAOYSA-N 0.000 description 1
- AUJMFWXVFMHABB-UHFFFAOYSA-N COC(c(nc[s]1)c1Br)=O Chemical compound COC(c(nc[s]1)c1Br)=O AUJMFWXVFMHABB-UHFFFAOYSA-N 0.000 description 1
- HQBHFUIUNYNCJC-UHFFFAOYSA-N COC(c1c(C(C(C2)N3OCC=C)=CCN2C3=O)[s]cn1)=O Chemical compound COC(c1c(C(C(C2)N3OCC=C)=CCN2C3=O)[s]cn1)=O HQBHFUIUNYNCJC-UHFFFAOYSA-N 0.000 description 1
- OJCLJYUHBRHVBJ-UHFFFAOYSA-N N#CC(CN(Cc1ccccc1)C1)=CC1=O Chemical compound N#CC(CN(Cc1ccccc1)C1)=CC1=O OJCLJYUHBRHVBJ-UHFFFAOYSA-N 0.000 description 1
- RHMUXOYWBXMBKP-UHFFFAOYSA-N N#CC(CN(Cc1ccccc1)C1)=CC1O Chemical compound N#CC(CN(Cc1ccccc1)C1)=CC1O RHMUXOYWBXMBKP-UHFFFAOYSA-N 0.000 description 1
- YDVVUNFRVPSJND-UHFFFAOYSA-N O=C(CN(Cc1ccccc1)C1)C=C1OS(C(F)(F)F)(=O)=O Chemical compound O=C(CN(Cc1ccccc1)C1)C=C1OS(C(F)(F)F)(=O)=O YDVVUNFRVPSJND-UHFFFAOYSA-N 0.000 description 1
- MWDBJWSENRUOJU-UHFFFAOYSA-N ON(C1C(c2c[o]nc2)=CCN2C1)C2=O Chemical compound ON(C1C(c2c[o]nc2)=CCN2C1)C2=O MWDBJWSENRUOJU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305701.3A EP3091018A1 (en) | 2015-05-07 | 2015-05-07 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP15305701.3 | 2015-05-07 | ||
| EP16305144 | 2016-02-08 | ||
| EP16305144.4 | 2016-02-08 | ||
| PCT/EP2016/060142 WO2016177862A1 (en) | 2015-05-07 | 2016-05-06 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016257338A1 AU2016257338A1 (en) | 2017-10-26 |
| AU2016257338B2 true AU2016257338B2 (en) | 2020-03-05 |
Family
ID=56083989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016257338A Ceased AU2016257338B2 (en) | 2015-05-07 | 2016-05-06 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10183943B2 (enExample) |
| EP (1) | EP3292125B1 (enExample) |
| JP (1) | JP6767392B2 (enExample) |
| KR (1) | KR102713561B1 (enExample) |
| CN (1) | CN107580595B (enExample) |
| AU (1) | AU2016257338B2 (enExample) |
| BR (1) | BR112017023359A2 (enExample) |
| CA (1) | CA2983674A1 (enExample) |
| CL (1) | CL2017002803A1 (enExample) |
| MX (1) | MX2017014080A (enExample) |
| RU (1) | RU2741496C2 (enExample) |
| TW (1) | TWI754613B (enExample) |
| WO (1) | WO2016177862A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170014135A1 (en) | 2015-07-14 | 2017-01-19 | Keith Edward Martin | Surgical tool |
| EP3300736B1 (en) * | 2016-09-30 | 2021-05-05 | Mutabilis | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections |
| EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP3357924A1 (en) | 2017-02-06 | 2018-08-08 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| ES2960952T3 (es) | 2018-08-09 | 2024-03-07 | Antabio Sas | Diazabiciclooctanonas como inhibidores de serina beta-lactamasas |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013150296A1 (en) * | 2012-04-02 | 2013-10-10 | Astrazeneca Ab | Heterobicyclic compounds as beta-lactamase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812635B1 (fr) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2835186B1 (fr) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| EP2231667B1 (en) * | 2008-01-18 | 2013-09-04 | Merck Sharp & Dohme Corp. | Beta-lactamase inhibitors |
| BR112013032974A2 (pt) * | 2011-08-30 | 2016-09-06 | Wockhardt Ltd | "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas". |
| SG11201406123TA (en) * | 2012-03-30 | 2014-10-30 | Cubist Pharm Inc | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS |
| CN104470906B (zh) | 2012-06-04 | 2016-08-24 | 爱尔克米亚 | 作为抵抗紫外线辐射的保护剂的亚氨基化合物 |
| US20140315876A1 (en) * | 2013-03-15 | 2014-10-23 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| BR112016008979B1 (pt) * | 2013-10-22 | 2023-04-25 | Wockhardt Limited | Composições farmacêuticas compreendendo agentes antibacterianos e seus usos |
| KR20170132301A (ko) * | 2015-03-31 | 2017-12-01 | 무타빌리스 | 신규한 헤테로사이클릭 화합물들 및 세균성 감염의 예방 또는 치료에서 그들의 용도 |
-
2016
- 2016-05-06 BR BR112017023359A patent/BR112017023359A2/pt not_active Application Discontinuation
- 2016-05-06 WO PCT/EP2016/060142 patent/WO2016177862A1/en not_active Ceased
- 2016-05-06 US US15/571,964 patent/US10183943B2/en active Active
- 2016-05-06 CA CA2983674A patent/CA2983674A1/en active Pending
- 2016-05-06 AU AU2016257338A patent/AU2016257338B2/en not_active Ceased
- 2016-05-06 TW TW105114242A patent/TWI754613B/zh not_active IP Right Cessation
- 2016-05-06 RU RU2017135321A patent/RU2741496C2/ru active
- 2016-05-06 KR KR1020177031802A patent/KR102713561B1/ko active Active
- 2016-05-06 EP EP16725377.2A patent/EP3292125B1/en active Active
- 2016-05-06 JP JP2017558028A patent/JP6767392B2/ja active Active
- 2016-05-06 MX MX2017014080A patent/MX2017014080A/es unknown
- 2016-05-06 CN CN201680026527.9A patent/CN107580595B/zh active Active
-
2017
- 2017-11-06 CL CL2017002803A patent/CL2017002803A1/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013150296A1 (en) * | 2012-04-02 | 2013-10-10 | Astrazeneca Ab | Heterobicyclic compounds as beta-lactamase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180093985A1 (en) | 2018-04-05 |
| KR102713561B1 (ko) | 2024-10-08 |
| TWI754613B (zh) | 2022-02-11 |
| AU2016257338A1 (en) | 2017-10-26 |
| RU2017135321A3 (enExample) | 2019-08-13 |
| BR112017023359A2 (pt) | 2018-07-17 |
| EP3292125B1 (en) | 2019-09-04 |
| KR20180002650A (ko) | 2018-01-08 |
| CL2017002803A1 (es) | 2018-05-11 |
| RU2741496C2 (ru) | 2021-01-26 |
| NZ736152A (en) | 2024-09-27 |
| WO2016177862A1 (en) | 2016-11-10 |
| MX2017014080A (es) | 2018-07-06 |
| CN107580595A (zh) | 2018-01-12 |
| CN107580595B (zh) | 2020-09-18 |
| RU2017135321A (ru) | 2019-04-10 |
| US10183943B2 (en) | 2019-01-22 |
| JP2018515504A (ja) | 2018-06-14 |
| JP6767392B2 (ja) | 2020-10-14 |
| EP3292125A1 (en) | 2018-03-14 |
| TW201643165A (zh) | 2016-12-16 |
| CA2983674A1 (en) | 2016-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7281527B2 (ja) | ベータラクタマーゼ阻害剤化合物 | |
| AU2016257338B2 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| EP3277686B1 (en) | Novel heterocyclic compounds and their use in preventing or treating bacterial infections | |
| KR102691642B1 (ko) | 헤테로사이클릭 화합물 및 이의 박테리아 감염의 예방 또는 치료 용도 | |
| TW201815390A (zh) | 包含抗生素化合物及雜環化合物之組合物及其於預防或治療細菌感染之用途 | |
| JP7589139B2 (ja) | 複素環式化合物及び細菌感染の予防又は治療へのそれらの使用 | |
| EP3091018A1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| BR112019006371B1 (pt) | Composto, composições farmacêuticas, uso de um composto e kits | |
| HK40002917B (zh) | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |